Treatment of Calcific Total Occlusions in Peripheral Artery Disease

NCT ID: NCT05551780

Last Updated: 2024-06-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

130 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-02-21

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prospective, multi-center, non-randomized, open label, clinical study intended to provide data to demonstrate safety and performance of the SoundBite Crossing System XS Peripheral.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The CaTO-PAD study includes a below-the-knee (BTK) sub-study (CaTO-BTK)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Total Occlusion of Artery of the Extremities

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SoundBite Crossing System - PAD

Use of the SoundBite Crossing System to cross calcified chronic total occlusions (above-the-knee or below-the-knee)

Group Type EXPERIMENTAL

SoundBite Crossing System

Intervention Type DEVICE

Use of the SoundBite Crossing System to cross calcified chronic total occlusions

SoundBite Crossing System - BTK

Use of the SoundBite Crossing System to cross calcified chronic total occlusions (below-the-knee)

Group Type EXPERIMENTAL

SoundBite Crossing System

Intervention Type DEVICE

Use of the SoundBite Crossing System to cross calcified chronic total occlusions

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SoundBite Crossing System

Use of the SoundBite Crossing System to cross calcified chronic total occlusions

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Scheduled for interventional treatment of de-novo lesion(s) of the following native arteries:

1. CaTO-PAD: infrainguinal
2. CaTO-BTK: infrapopliteal
2. Have at least one chronic total occlusion (CTO) with no flow observed in the distal lesion except the flow from collateral circulation
3. Presenting with the following:

1. CaTO-PAD: claudication or CLI (Rutherford Clinical Category 2-5) of the target limb
2. CaTO-BTK Sub-Study: - Category 4 or 5 only for CaTO-BTK Sub-Study CaTO-PAD: claudication or CLI (Rutherford Clinical Category 2-5) of the target limb
4. Age of \> 18 years
5. Have been informed of the nature of the study, agrees to participate, and has signed the approved study consent form
6. Target lesion calcification is at least moderate by PARC definition (see Section 15)
7. Target lesion is refractory as demonstrated by a failed attempt with a guidewire

Exclusion Criteria

1. Any medical condition that would make subject an inappropriate candidate for interventional treatment as determined by the Investigator, including the following:

1. Glomerular filtration rate \<30 ml/min
2. Mortality expected within 30 days
2. Already enrolled in an investigational interventional study that would interfere with study endpoints
3. Target lesion is crossed intraluminally with a conventional guidewire
4. Treatment of an inflow lesion prior to target lesion treatment results in no reflow, thrombus formation, abrupt closure, distal embolization, dissection or perforation requiring treatment
5. Women who are pregnant or breastfeeding
Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

SoundBite Medical Solutions, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

George Adams, MD

Role: PRINCIPAL_INVESTIGATOR

UNC REX Hospital, Raleigh, NC, USA

Michael Lichtenberg, MD

Role: PRINCIPAL_INVESTIGATOR

Angiology Clinic and Vascular Centre, Arnsberg, Germany

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Palm Vascular Centers

Fort Lauderdale, Florida, United States

Site Status RECRUITING

UNC REX Hospial

Raleigh, North Carolina, United States

Site Status NOT_YET_RECRUITING

Lifespan - The Miriam Hospital

Providence, Rhode Island, United States

Site Status RECRUITING

Medizinische Universität Graz

Graz, , Austria

Site Status NOT_YET_RECRUITING

Angiology Clinic and Vascular Centre

Arnsberg, , Germany

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States Austria Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

John Schultz

Role: CONTACT

514-312-9181

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jennifer Gimeno

Role: primary

Rebecca Palermo

Role: primary

Lina Felix

Role: primary

Romana Schuh

Role: primary

Simone Müller

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

INT-PER-2022-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.